866-897-8297

Call Is Confidential & Toll Free

Hyzaar

Hyzaar is an angiotensin-receptor blocker (ARB ) that may be used alone or with other agents to treat hypertension. Hyzaar and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS ); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE ) inhibitors, ARBs do not have the adverse effect of dry cough. Hyzaar may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.

Hyzaar is the first of a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Hyzaar and its longer acting active metabolite, E-3174, are specific and selective type-1 angiotensin II receptor (AT1) antagonists which block the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.

Hypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) stimulation, LD50= 1000 mg/kg (orally in rat)

Imprints


Drug: Hyzaar
Strength: 12.5 Mg / 50 Mg
Pill Imprint: HYZAAR MRK 717
Color: Yellow
Shape: Egg-shape

View Images & Details

Drug: Hyzaar
Strength: 12.5 Mg / 50 Mg
Pill Imprint: 717
Color: Yellow
Shape: Elliptical / Oval

View Images & Details

Drug: Hyzaar
Strength: 25 Mg / 100 Mg
Pill Imprint: 747
Color: Yellow
Shape: Elliptical / Oval

View Images & Details

Drug: Hyzaar
Strength: 25 Mg / 100 Mg
Pill Imprint: HYZAAR MRK 747
Color: Yellow
Shape: Egg-shape

View Images & Details

Drug: Hyzaar
Strength: 12.5 Mg / 100 Mg
Pill Imprint: 745
Color: White
Shape: Elliptical / Oval

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?